| Chad Casebeer, DMD | |
|
14210 Se Sunnyside Rd Ste 200, Clackamas, OR 97015-5242 | |
| (503) 451-5104 | |
| Not Available |
| Full Name | Chad Casebeer |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 14210 Se Sunnyside Rd Ste 200, Clackamas, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194404954 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | D11851 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Chad Casebeer, DMD 9980 Sw Citation Pl, Beaverton, OR 97008-8060 Ph: (503) 798-8851 | Chad Casebeer, DMD 14210 Se Sunnyside Rd Ste 200, Clackamas, OR 97015-5242 Ph: (503) 451-5104 |
News Archive
Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb).
Speaking on Monday at a conference on communicable diseases in the eastern Europe and Central Asia region, where AIDS is a growing problem, Russian Foreign Minister Sergei Lavrov made Russia's case for poppy crop eradication by U.S. and NATO forces in Afghanistan asserting that the West "is aggravating the HIV/AIDS problem in Russia and the West by refusing to use its forces to destroy opium crops in Afghanistan," Reuters reports.
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
Inhaled Nitric Oxide (iNO) is a drug approved by the Food and Drug Administration that is commonly used in term and near-term neonates who have severe respiratory failure caused by pulmonary hypertension. Over the last decade there have been multiple large studies trying to determine a clinical use for iNO in preterm neonates, but despite evidence of short-term benefit, this drug has not been shown to improve long-term outcomes in preemies.
Researchers in the Netherlands have identified a chemical agent that may be a, if not the, culprit in bronchiolitis obliterans syndrome (BOS), or "popcorn worker's lung," a severe occupational lung disease first noted in 2001 among workers at an American plant that makes microwaveable popcorn.
› Verified 8 days ago
Michael Allan Brown, D.M.D., P.C. Dentist Medicare: Not Enrolled in Medicare Practice Location: 12014 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-698-6900 | |
Dr. David Kenneth Walker, DMD Dentist Medicare: Medicare Enrolled Practice Location: 10209 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 503-353-3900 | |
Dustin Michael Davis, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 11411 Se Sunnyside Rd Ste 101, Clackamas, OR 97015 Phone: 503-855-5100 | |
Dr. Grant Alexander, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 16144 Se Happy Valley Town Center Dr, Clackamas, OR 97086 Phone: 503-667-2400 | |
Dr. David Edward Doyle Jr., DDS Dentist Medicare: Medicare Enrolled Practice Location: 10121 Se Sunnyside Rd, Suite 320, Clackamas, OR 97015 Phone: 503-786-5080 Fax: 503-786-3483 | |
Dr. Daniel Miller, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 10163 Se Sunnyside Rd, Suite 414, Clackamas, OR 97015 Phone: 503-653-4079 |